PCa cells were plated in 6-well plates in triplicate and allowed to adhere for 24Hrs prior to treatment with doxycycline (1μg/ml) or ATRA (Sigma-Aldrich, St. Louis, MO, USA). At the indicated time points, cells were trypsinized, pelleted, and resuspended in a known volume. Cell counts were established using a Countess
automated cell counter. Live versus dead cells were quantified by trypan blue exclusion using a Countess
automated cell counter. Cell growth was determined by normalizing cell numbers at the indicated time points to the number of cells plated. Doubling times were determined using relative growth values from T24 and T96 time points.
The viability of cells expressing CD38 treated with FK866 was determined using
Cell Titer-Glo 2.0 (Promega, Madison, WI, USA). Briefly, cells treated with vehicle or doxycycline (1μg/mL) were plated in 96-well plates (N=7) and allowed to adhere for 8Hrs prior to the addition of FK866. Luminescence was detected using a
FLUOstar Optima spectrometer (BMG Labtech, Cary, NC, USA) and viability was determined relative to control.
Chmielewski J.P., Bowlby S.C., Wheeler F.B., Shi L., Sui G., Davis A.L., Howard T.D., D’Agostino RB J.r., Miller L.D., Sirintrapun S.J., Cramer S.D, & Kridel S.J. (2018). CD38 Inhibits Prostate Cancer Metabolism and Proliferation by Reducing Cellular NAD+ Pools. Molecular cancer research : MCR, 16(11), 1687-1700.